Saba holds 25.97% of BlackRock ESG Capital Allocation Term Trust (ECAT)
Rhea-AI Filing Summary
Saba Capital Management and affiliates report a large position in BlackRock ESG Capital Allocation Term Trust. The Schedule 13D/A (Amendment No. 26) shows that Saba Capital Management, L.P., Saba Capital Management GP, LLC and Boaz R. Weinstein collectively beneficially own 25,798,288 common shares, representing 25.97% of the trust’s outstanding common shares, based on 99,345,793 shares outstanding as of 6/30/25. The filing states that approximately $383,502,360 was paid to acquire these shares, using investor subscription proceeds, related capital appreciation and margin borrowings in the ordinary course of business. The funds and accounts advised by Saba Capital are entitled to dividends and sale proceeds on the shares, and recent trading activity from 11/25/25 to 1/21/26 is listed in an attached schedule.
Positive
- None.
Negative
- None.
Insights
Saba discloses a 25.97% economic stake in ECAT, signaling substantial influence potential.
The filing shows that Saba Capital Management, its general partner and Boaz R. Weinstein together report beneficial ownership of 25,798,288 common shares of BlackRock ESG Capital Allocation Term Trust, equal to 25.97% of shares outstanding as of 6/30/25. This level of ownership can be significant in a closed‑end fund context because it represents a sizeable voting bloc on matters that come before shareholders.
The disclosure notes that about $383,502,360 was paid to acquire the position, funded by investor capital, appreciation and margin borrowings, which indicates meaningful capital at work. The amendment updates Items 3, 5 and 7, including transaction detail in Schedule A from 11/25/25 through 1/21/26. While the filing lists the stake and funding sources, it states the purpose of transaction as not applicable, so any future governance or portfolio implications would depend on subsequent shareholder actions or additional disclosures.
FAQ
What ownership stake in ECAT does Saba Capital report in this Schedule 13D/A?
How much did Saba Capital pay to acquire its ECAT shares?
How were Saba Capital’s ECAT purchases funded?
Who are the reporting persons in this ECAT Schedule 13D/A amendment?
What is the significance of Amendment No. 26 to Saba’s ECAT Schedule 13D?
Do Saba Capital and its clients receive dividends and sale proceeds from their ECAT shares?
What is the date of the event that triggered this ECAT Schedule 13D/A filing?